FETAX Assay for Evaluation of Developmental Toxicity

Methods in Molecular Biology

Volumn 691, Issue , 2011, Pages 257-269

  Mouche, Isabelle ^a   Malesic, Laure ^a   Gillardeaux, Olivier ^a  

^a SANOFI   (France)

Author keywords

Development; Embryo; FETAX; Teratogen; Teratogenesis; Toxicity; Xenopus laevis

Indexed keywords

ANIMAL; ANIMAL EMBRYO; ARTICLE; CONGENITAL MALFORMATION; CULTURE TECHNIQUE; DOSE RESPONSE; DRUG DEVELOPMENT; DRUG EFFECT; FEMALE; FERTILIZATION IN VITRO; HUMAN; LARVA; MALE; METHODOLOGY; OOCYTE; PHYSIOLOGY; PRENATAL DEVELOPMENT; TOXICITY TESTING; XENOPUS LAEVIS;

ABNORMALITIES, DRUG-INDUCED; ANIMALS; CULTURE TECHNIQUES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; EMBRYO, NONMAMMALIAN; FEMALE; FERTILIZATION IN VITRO; HUMANS; LARVA; MALE; OVUM; TOXICITY TESTS; XENOPUS LAEVIS;

MLCS; MLOWN;

EID: 79952197823     PISSN: 10643745     EISSN: 19406029     Source Type: Book Series    
DOI: 10.1007/978-1-60761-849-2_15     Document Type: Chapter

References (9)

1. ASTM. (1998) Standard guide for conducting the frog embryo teratogenesis assay – Xenopus. Designation E 1439-98. In Annual book of ASTM standards, Vol 11.5. American Society for Testing and Materials, Philadelphia, pp. 825–836.
2. Bantle, J.A., Finch R.A., Burton, D.T., Fort, D.J., Dawson, D.A., Linder, G., Rayburn, J.R., Hull, M., Kumsher-King, M., Gaudet-Hull, A.M., and Turley, S.D. (1996) FETAX interlaboratory validation study: Phase III – Part 1 testing. J. Appl. Toxicol. 16(6), 517–528.
3. Sipe, C.W., and Saha, M.S. (2007) The use of microarray technology in non mammalian vertebrate systems. In Microarrays: Volume II: Applications and Data Analysis. Methods in Molecular Biology. Vol 382 (Rampal, J.B., ed.), Humana, Totowa, NJ, pp. 1–16.
4. Vallée, M., Aiba, K., Piao, Y., Palin, M.F., Ko, M.S., and Sirard, M.A. (2008) Comparative analysis of oocyte transcript profiles reveals a high degree of conservation among species. Reproduction 135(4), 439–448.
5. Bantle, J.A., Dumont, J.N., Finch, R.A., Linder G., and Fort, D.J. (1998) Atlas of abnormalities, a guide for the performance of FETAX, 2nd ed. Oklahoma State University, Stillwater, OK.
6. Fort, D.J., Stover, E.L., Bantle, J.A., Rayburn, J.R., Hull, M.A., Finch, R.A., Burton, D.T., Turley, S.D., Dawson, D.A., Linder, G., Buchwalter, D., Dumont, J.N., Kumsher-King, M., and Gaudet-Hull, A.M. (1998) Phase III interlaboratory study of FETAX, Part 2: interlaboratory validation of an exogenous metabolic activation system for frog embryo teratogenesis assay-Xenopus (FETAX). Drug Chem. Toxicol. 21(1), 1–14.
7. Bantle, J.A., Finch, R.A., Fort, D.J., Stover, E.L., Hull, M., Kumsher-King, M., and Gaudet-Hull, A.M. (1999) Phase III interlaboratory study of FETAX. Part 3. FETAX Validation using 12 compounds with and without an exogenous metabolic activation system. J. Appl. Toxicol. 19, 447–472.
8. Fort, D.J., Rogers, R.L., Stover, E.L., and Finch, R.A. (2001) Optimization of an exogenous metabolic activation system for FETAX. I. Post-isolation rat liver microsome mixtures. Drug Chem. Toxicol. 24(2), 103–115.
9. Fort, D.J., Rogers, R.L., Paul, R.R., Stover, E.L., and Finch, R.A. (2001) Optimization of an exogenous metabolic activation system for FETAX. II. Preliminary evaluation. Drug Chem. Toxicol. 24(2), 117–127.